CA1319107C - Compositions empechant le transport de glucose - Google Patents

Compositions empechant le transport de glucose

Info

Publication number: CA1319107C
Authority: CA; Canada
Prior art keywords: agent; tumor; glucose; cell; tissue surrounding
Prior art date: 1988-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000568512A

Other languages

English (en)

Inventor

Rudolf Edgard Falk

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-02

Filing date

1988-06-02

Publication date

1993-06-15

1988-06-02 Application filed by Individual filed Critical Individual

1988-06-02 Priority to CA000568512A priority Critical patent/CA1319107C/fr

1993-06-15 Application granted granted Critical

1993-06-15 Publication of CA1319107C publication Critical patent/CA1319107C/fr

2010-06-15 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000009472 formulation Methods 0.000 title claims abstract description 20
239000000203 mixture Substances 0.000 title claims abstract description 20
230000002401 inhibitory effect Effects 0.000 title claims abstract description 12
230000006377 glucose transport Effects 0.000 title description 5
206010028980 Neoplasm Diseases 0.000 claims abstract description 127
239000003795 chemical substances by application Substances 0.000 claims abstract description 70
201000011510 cancer Diseases 0.000 claims abstract description 51
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 37
239000008103 glucose Substances 0.000 claims abstract description 35
230000035515 penetration Effects 0.000 claims abstract description 30
230000001413 cellular effect Effects 0.000 claims abstract description 20
231100000252 nontoxic Toxicity 0.000 claims abstract description 19
230000003000 nontoxic effect Effects 0.000 claims abstract description 19
231100000241 scar Toxicity 0.000 claims abstract description 17
230000032258 transport Effects 0.000 claims abstract description 16
102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims abstract description 12
108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 claims abstract description 12
239000012528 membrane Substances 0.000 claims abstract description 11
230000009056 active transport Effects 0.000 claims abstract description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 68
210000004027 cell Anatomy 0.000 claims description 56
VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims description 56
IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims description 31
IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 claims description 31
235000019139 phlorizin Nutrition 0.000 claims description 31
ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims description 28
YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims description 28
229940126902 Phlorizin Drugs 0.000 claims description 27
229940016409 methylsulfonylmethane Drugs 0.000 claims description 25
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 25
239000003937 drug carrier Substances 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 6
229930182480 glucuronide Natural products 0.000 claims 5
IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 claims 4
150000008134 glucuronides Chemical class 0.000 claims 3
210000000170 cell membrane Anatomy 0.000 claims 2
-1 phlorizin glucuronide Chemical class 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
238000002512 chemotherapy Methods 0.000 description 24
210000001519 tissue Anatomy 0.000 description 24
238000011282 treatment Methods 0.000 description 19
238000000015 thermotherapy Methods 0.000 description 16
206010020843 Hyperthermia Diseases 0.000 description 9
230000036031 hyperthermia Effects 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
210000004185 liver Anatomy 0.000 description 7
206010061289 metastatic neoplasm Diseases 0.000 description 7
230000004044 response Effects 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000001015 abdomen Anatomy 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 4
238000000034 method Methods 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
201000005249 lung adenocarcinoma Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
JYLYYGIKROUWRG-UHFFFAOYSA-N methane;methylsulfonylmethane Chemical compound C.CS(C)(=O)=O JYLYYGIKROUWRG-UHFFFAOYSA-N 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027450 Metastases to abdominal cavity Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000006809 Pancreatic Fistula Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
230000003890 fistula Effects 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
108010070004 glucose receptor Proteins 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000009217 hyperthermia therapy Methods 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
201000002529 islet cell tumor Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
229960003538 lonidamine Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000001254 nonsecretory effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
235000021391 short chain fatty acids Nutrition 0.000 description 1
150000004666 short chain fatty acids Chemical class 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000568512A 1988-06-02 1988-06-02 Compositions empechant le transport de glucose Expired - Fee Related CA1319107C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000568512A CA1319107C (fr)	1988-06-02	1988-06-02	Compositions empechant le transport de glucose

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000568512A CA1319107C (fr)	1988-06-02	1988-06-02	Compositions empechant le transport de glucose

Publications (1)

Publication Number	Publication Date
CA1319107C true CA1319107C (fr)	1993-06-15

Family

ID=4138131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000568512A Expired - Fee Related CA1319107C (fr)	1988-06-02	1988-06-02	Compositions empechant le transport de glucose

Country Status (1)

Country	Link
CA (1)	CA1319107C (fr)

1988
- 1988-06-02 CA CA000568512A patent/CA1319107C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2004-06-15	MKLA	Lapsed

Publication	Publication Date	Title
US6448287B1 (en)	2002-09-10	Treatment of cancer using lipoic acid in combination with ascorbic acid
US5225404A (en)	1993-07-06	Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
RU2162327C2 (ru)	2001-01-27	Лечение рака и профилактика метастазирования
Rich et al.	1985	A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy.
US5639787A (en)	1997-06-17	Therapeutic method for the treatment of cancer
Reitemeier et al.	1970	Combination chemotherapy in gastrointestinal cancer
EP2063881B1 (fr)	2019-05-08	Composition et méthode pour administrer efficacement et sans danger un halopyruvate pour traiter un cancer
JPS6388128A (ja)	1988-04-19	腫瘍細胞転移抑制剤
Kajanti et al.	1994	Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system: a phase II study
WO2017165667A9 (fr)	2018-05-11	Utilisation de caroténoïdes trans bipolaires avec une chimiothérapie et une radiothérapie en vue du traitement d'un cancer
EP1272199A1 (fr)	2003-01-08	Therapies combinees induisant un effet de deterioration vasculaire
AU2001242581A1 (en)	2002-01-03	Combination therapies with vascular damaging activity
Ariel	1970	Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
US4384001A (en)	1983-05-17	Treatment of tumors with thiazolidine-4-carboxylic acid
Ike et al.	1991	Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly (L-lactic acid) microspheres
JPH0242813B2 (fr)	1990-09-26
CA1319107C (fr)	1993-06-15	Compositions empechant le transport de glucose
JP2974740B2 (ja)	1999-11-10	肝臓、血液および血漿のアデノシン５’‐三リン酸濃度を増加させるための薬剤
Collier et al.	1976	Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma
US7879814B2 (en)	2011-02-01	Methods and therapeutic compositions in the treatment of advanced cancer
Ramirez et al.	1993	Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases
EA004570B1 (ru)	2004-06-24	Применение производного антрациклина для лечения опухоли печени
Kakizaki et al.	1987	Preoperative one-shot intra-arterial infusion chemotherapy for bladder cancer
RU2211035C1 (ru)	2003-08-27	Противотуберкулезный препарат
Stathopoulos et al.	1995	Effect of adriamycin, 5-Fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer